Boehringer Ingelheim News
Pharmaceutical news of Boehringer Ingelheim GmbH in Germany
Boehringer Ingelheim and GlaxoSmithKline back EFA`s call for urgent improvements in care for people with lung disease this World COPD Day
Brussels, Ingelheim and London, 18 November 2009 - Boehringer Ingelheim and GSK, companies with a strong heritage in COPD (chronic obstructive pulmonary disease) and a commitment to improved patient care, have today announced their support of The European Federation of Allergy and Airways Diseases Patients` Associations` (EFA) call for urgent improvement in the care of people with COPD.
Flibanserin demonstrates efficacy and tolerability in pivotal Phase III Trials in pre-menopausal women with Hypoactive Sexual Desire Disorder (HSDD)
Ingelheim/ Germany, 16 November 2009 2E8 Data from pooled, pivotal Phase III clinical trials demonstrate that flibanserin 100mg taken once daily at bedtime significantly increased the number of Satisfying Sexual Events (SSEs) and sexual desire while significantly decreasing the distress associated with Hypoactive Sexual Desire Disorder (HSDD).1 Flibanserin is an investigational compound that is be
Boehringer Ingelheim announces record productivities for CHO cells using the BI-HEX® technology platform
A team of Boehringer Ingelheim scientists reports another milestone in the development of the BI-HEX® technology platform. A record productivity of more than 100 picogramms per cell per day was achieved in inoculum and fed-batch cultures of BI-HEX® Chinese hamster ovary (CHO) cell lines expressing a therapeutic monoclonal antibody.
Heinrich Wieland Prize 2009 awarded for outstanding achievements in the synthesis of key natural products
Ingelheim, Munich/Germany, 29 October 2009 - Professor Steven V. Ley of the Cambridge University (UK) was awarded this year’s Heinrich Wieland Prize in appreciation of his extraordinary scientific achievements in the fields of synthesis, structural analysis and biological characterization of natural products.
Boehringer Ingelheim Animal Health closes deal to acquire a significant portion of the Fort Dodge Animal Health Business from Pfizer
Ingelheim/Germany and St. Joseph/MO, 26 October 2009 - Boehringer Ingelheim, a global pharmaceutical group of companies, together with its U.S. animal health business Boehringer Ingelheim Vetmedica, Inc., announced today that it has closed its deal with Pfizer to acquire a significant portion of the Fort Dodge Animal Health business.
CHMP issues positive opinion for Micardis® (telmisartan) as the first treatment in its class to reduce the risk of cardiovascular (CV) morbidity in high CV risk patients
Ingelheim/Germany, 23 October 2009: Boehringer Ingelheim announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA) has issued a positive opinion for the approval of Micardis® (telmisartan) for the reduction of cardiovascular morbidity in patients with:
FDA approves Twynsta® (telmisartan plus amlodipine) a new single pill combination that delivers powerful and consistent blood pressure reductions throughout 24 hours
- Twynsta® delivers very powerful blood pressure (BP) reductions of up to 40/29 mmHg1 and a 24-hour BP response rate of up to 98%2 for hypertensive patients at risk of cardiovascular (CV) events
- Twynsta® combines the proven evidence base in CV outcomes of telmisartan and amlodipine3-9in a convenient single pill
- Twynsta® achieves superior BP reductions compared to
FDA approves Micardis® (telmisartan) as the first treatment in its class to reduce the risk of heart attack, stroke, or death from cardiovascular causes in patients at high cardiovascular risk who are unable to take ACE inhibitors
Micardis® is now indicated for cardiovascular (CV) risk reduction in patients with intolerance to angiotensin-converting enzyme (ACE) inhibitors.
Boehringer Ingelheim receives approval from the European Commission for Mirapexin®/Sifrol® prolonged-release, once daily tablet for the treatment of Parkinson’s disease
Ingelheim/Germany, 14 October 2009 – Boehringer Ingelheim today announced that the Mirapexin®/Sifrol® (pramipexole) new prolonged-release, once daily tablet has been granted marketing authorisation by the European Commission in all EU/EEA*) countries for the treatment of early and advanced idiopathic Parkinson’s disease (PD).
Access to HIV medication
Boehringer Ingelheim has repeatedly and clearly stated that patents must not prevent access from life-saving drugs for HIV patients living in resource limited settings. In line with this and in order to accelerate access to anti-retroviral medicines, the company has initiated non-assert declarations in May 2007, well before the idea of the UNITAID patent pool was conceived.
